These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
710 related articles for article (PubMed ID: 17589295)
21. Adenovirally transduced dendritic cells induce bispecific cytotoxic T lymphocyte responses against adenovirus and cytomegalovirus pp65 or against adenovirus and Epstein-Barr virus EBNA3C protein: a novel approach for immunotherapy. Hamel Y; Blake N; Gabrielsson S; Haigh T; Jooss K; Martinache C; Caillat-Zucman S; Rickinson AB; Hacein-Bey S; Fischer A; Cavazzana-Calvo M Hum Gene Ther; 2002 May; 13(7):855-66. PubMed ID: 11975851 [TBL] [Abstract][Full Text] [Related]
22. A canarypox vector-expressing cytomegalovirus (CMV) phosphoprotein 65 induces long-lasting cytotoxic T cell responses in human CMV-seronegative subjects. Berencsi K; Gyulai Z; Gönczöl E; Pincus S; Cox WI; Michelson S; Kari L; Meric C; Cadoz M; Zahradnik J; Starr S; Plotkin S J Infect Dis; 2001 Apr; 183(8):1171-9. PubMed ID: 11262198 [TBL] [Abstract][Full Text] [Related]
23. Isolation and expansion of human adenovirus-specific CD4+ and CD8+ T cells according to IFN-gamma secretion for adjuvant immunotherapy. Feuchtinger T; Lang P; Hamprecht K; Schumm M; Greil J; Jahn G; Niethammer D; Einsele H Exp Hematol; 2004 Mar; 32(3):282-9. PubMed ID: 15003314 [TBL] [Abstract][Full Text] [Related]
24. Gene transfer for activation of CMV specific T cells. André-Schmutz I; Dal Cortivo L; Hamel Y; Cavazzana-Calvo M Hum Immunol; 2004 May; 65(5):565-70. PubMed ID: 15172458 [TBL] [Abstract][Full Text] [Related]
25. Dendritic cells expand Epstein Barr virus specific CD8+ T cell responses more efficiently than EBV transformed B cells. Subklewe M; Sebelin K; Block A; Meier A; Roukens A; Paludan C; Fonteneau JF; Steinman RM; Münz C Hum Immunol; 2005 Sep; 66(9):938-49. PubMed ID: 16360833 [TBL] [Abstract][Full Text] [Related]
26. Expansion of T cells targeting multiple antigens of cytomegalovirus, Epstein-Barr virus and adenovirus to provide broad antiviral specificity after stem cell transplantation. Hanley PJ; Shaffer DR; Cruz CR; Ku S; Tzou B; Liu H; Demmler-Harrison G; Heslop HE; Rooney CM; Gottschalk S; Bollard CM Cytotherapy; 2011 Sep; 13(8):976-86. PubMed ID: 21539497 [TBL] [Abstract][Full Text] [Related]
27. Clinical grade generation of hexon-specific T cells for adoptive T-cell transfer as a treatment of adenovirus infection after allogeneic stem cell transplantation. Feuchtinger T; Richard C; Joachim S; Scheible MH; Schumm M; Hamprecht K; Martin D; Jahn G; Handgretinger R; Lang P J Immunother; 2008; 31(2):199-206. PubMed ID: 18481389 [TBL] [Abstract][Full Text] [Related]
28. Reconstitution of the latent T-lymphocyte response to Epstein-Barr virus is coincident with long-term recovery from posttransplant lymphoma after adoptive immunotherapy. Sherritt MA; Bharadwaj M; Burrows JM; Morrison LE; Elliott SL; Davis JE; Kear LM; Slaughter RE; Bell SC; Galbraith AJ; Khanna R; Moss DJ Transplantation; 2003 May; 75(9):1556-60. PubMed ID: 12792514 [TBL] [Abstract][Full Text] [Related]
29. Identification of three HLA-A*0201-restricted cytotoxic T cell epitopes in the cytomegalovirus protein pp65 that are conserved between eight strains of the virus. Solache A; Morgan CL; Dodi AI; Morte C; Scott I; Baboonian C; Zal B; Goldman J; Grundy JE; Madrigal JA J Immunol; 1999 Nov; 163(10):5512-8. PubMed ID: 10553078 [TBL] [Abstract][Full Text] [Related]
30. Evaluation of cytomegalovirus-specific T-cell reconstitution in patients after various allogeneic haematopoietic stem cell transplantation using interferon-gamma-enzyme-linked immunospot and human leucocyte antigen tetramer assays with an immunodominant T-cell epitope. Ohnishi M; Sakurai T; Heike Y; Yamazaki R; Kanda Y; Takaue Y; Mizoguchi H; Kawakami Y Br J Haematol; 2005 Nov; 131(4):472-9. PubMed ID: 16281937 [TBL] [Abstract][Full Text] [Related]
31. Expansion of human CMV-specific cytotoxic T lymphocytes to a clinical scale: a simple culture system using tetrameric HLA-peptide complexes. Watanabe N; Kamachi Y; Koyama N; Hama A; Liang J; Nakamura Y; Yamamoto T; Isomura M; Kudo K; Kuzushima K; Kojima S Cytotherapy; 2004; 6(5):514-22. PubMed ID: 15512918 [TBL] [Abstract][Full Text] [Related]
33. CMV-, EBV- and ADV-specific T cell immunity: screening and monitoring of potential third-party donors to improve post-transplantation outcome. Sukdolak C; Tischer S; Dieks D; Figueiredo C; Goudeva L; Heuft HG; Verboom M; Immenschuh S; Heim A; Borchers S; Mischak-Weissinger E; Blasczyk R; Maecker-Kolhoff B; Eiz-Vesper B Biol Blood Marrow Transplant; 2013 Oct; 19(10):1480-92. PubMed ID: 23891747 [TBL] [Abstract][Full Text] [Related]
34. Sustained CD8+ T-cell immune response to a novel immunodominant HLA-B*0702-associated epitope derived from an Epstein-Barr virus helicase-primase-associated protein. Turcanová V; Höllsberg P J Med Virol; 2004 Apr; 72(4):635-45. PubMed ID: 14981767 [TBL] [Abstract][Full Text] [Related]
35. Dendritic cells improve the generation of Epstein-Barr virus-specific cytotoxic T lymphocytes for the treatment of posttransplantation lymphoma. Wheatley GH; McKinnon KP; Iacobucci M; Mahon S; Gelber C; Lyerly HK Surgery; 1998 Aug; 124(2):171-6. PubMed ID: 9706135 [TBL] [Abstract][Full Text] [Related]
36. CD8high (CD57+) T cells in normal, healthy individuals specifically suppress the generation of cytotoxic T lymphocytes to Epstein-Barr virus-transformed B cell lines. Wang EC; Lehner PJ; Graham S; Borysiewicz LK Eur J Immunol; 1994 Nov; 24(11):2903-9. PubMed ID: 7525311 [TBL] [Abstract][Full Text] [Related]
37. Immunotherapy for Hodgkin's disease. Rooney CM; Bollard C; Huls MH; Gahn B; Gottschalk S; Wagner HJ; Anderson R; Prentice HG; Brenner MK; Heslop HE Ann Hematol; 2002; 81 Suppl 2():S39-42. PubMed ID: 12611071 [TBL] [Abstract][Full Text] [Related]
38. Human cytotoxic T lymphocytes. III. Large numbers of peripheral blood T cells clonally develop into allorestricted anti-viral cytotoxic T cell populations in vitro. Kabelitz D; Herzog WR; Heeg K; Wagner H; Reimann J J Mol Cell Immunol; 1987; 3(1):49-60. PubMed ID: 2855406 [TBL] [Abstract][Full Text] [Related]
39. Characterization of host immunity to cytomegalovirus pp150 (UL32). La Rosa C; Wang Z; Lacey SF; Markel SF; Sharma MC; Martinez J; Lalimarmo MM; Diamond DJ Hum Immunol; 2005 Feb; 66(2):116-26. PubMed ID: 15694996 [TBL] [Abstract][Full Text] [Related]
40. Rapid generation of full clinical-grade human antiadenovirus cytotoxic T cells for adoptive immunotherapy. Aïssi-Rothé L; Decot V; Venard V; Jeulin H; Salmon A; Clement L; Kennel A; Mathieu C; Dalle JH; Rauser G; Cambouris C; de Carvalho M; Stoltz JF; Bordigoni P; Bensoussan D J Immunother; 2010 May; 33(4):414-24. PubMed ID: 20386465 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]